Or Refractory B-cell Non-hodgkin Lymphoma

• CLINICAL_TRIALS trial_result · 2026-04-06
  Clinical Trial Update: Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]

  This Phase 1 trial update reports a combination of tazemetostat with zanubrutinib and an anti-CD20 monoclonal antibody for relapsed or refra…

• CLINICAL_TRIALS research · 2026-03-19
  Clinical Trial Update: A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101) [Phase 1]

  Phase 1 study evaluating MK-1045 (CN201) for safety and early activity in relapsed or refractory B-cell non-Hodgkin lymphoma; recruitment is…

• CLINICAL_TRIALS research · 2026-01-16
  Clinical Trial Update: Clinical Study on the Safety and Efficacy of CD20/CD19 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [NA]

  A clinical study is evaluating the safety and efficacy of a CD20/CD19 cell injection for relapsed or refractory B-cell non-Hodgkin lymphoma,…

• CLINICAL_TRIALS research · 2022-12-16
  Clinical Trial Update: Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation [Phase 2]

  Phase 2 trial of tazemetostat in relapsed or refractory B-cell non-Hodgkin's lymphoma with EZH2 mutation completed.

• CLINICAL_TRIALS trial_result · 2022-11-10
  Clinical Trial Update: A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma [Phase 1]

  Phase 1 trial of tazemetostat in relapsed or refractory B-cell non-Hodgkin's lymphoma completed with results posted in 2022.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS trial_result · 2021-11-05
  Clinical Trial Update: Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma [Phase 2]

  Phase 2 trial evaluating pralatrexate for relapsed or refractory B-cell non-Hodgkin's lymphoma has completed, with results posted in 2021.

• CLINICAL_TRIALS trial_result · 2021-03-16
  Clinical Trial Update: Study of Chidamide as a Single-agent Treatment for Patients With Relapse or Refractory B-NHL [Phase 2]

  A Phase 2 clinical trial evaluating chidamide as a single-agent therapy for relapsed or refractory B-cell non-Hodgkin's lymphoma.